A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of two drugs that change the immune system and
tumor as a possible treatment for metastatic or unresectable stage III or IV cutaneous
melanoma.
The names of the study drugs involved in this study are:
- Atezolizumab
- Bevacizumab